UBC investigators report the success of triple drug therapy at the Vancouver International AIDS Conference. New standard of care incorporating viral load monitoring and trip therapy is unveiled at this conference.
B.C. becomes the first Canadian province to adopt triple drug therapy and viral load testing for all eligible patients in a publicly funded plan and immediately sees dramatically reduced HIV/AIDS related morbidity and mortality.
BC-CfE research findings revealed an explosive outbreak of HIV and hepatitis C in injection drug users in Vancouver’s Downtown Eastside.
CLICK FOR NEW HIV-1 RESISTANCE GENOTYPE REPORT NOTICE
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’. For more details and example reports, please click on the button below
